Farmacie pro praxi. 2023;19(2):124-127
Technological possibilities to ensure drug abuse protection
- Ústav farmaceutické technologie, Farmaceutická fakulta, Masarykova univerzita, Brno
The non-therapeutic use of medicines and its increase is a global and societal problem. It affects not only the health sector, but it also has significant human, social and economic consequences. The development of dosage forms (DFs) to reduce or prevent the abuse of medicines is one step in a comprehensive solution to this problem. The last decade has brought the development of more robust DFs capable of reducing drug abuse. Technologies and strategies to prevent drug abuse typically target common or expected application routes. Technology can limit the extractability of the active ingredient and the bioavailability after DF manipulation, prevent drug distribution in the body after using an alternative administration route, reduce the effect of the substance after manipulation, or make the effect less pleasant. The technological approach often focuses on formulations that are physically and chemically resistant, often also capable of modifying the drug's pharmacokinetics after adverse manipulation. Other options, such as drug antagonists, prodrugs, aversive agents, and innovative excipients, are also gaining attention.
Keywords: modification of dosage form, tamper resistant, opioid analgesics, solid dosage forms, addiction, drug abuse.
Accepted: May 29, 2023; Published: June 7, 2023 Show citation
References
- Opioids. Organisation for Economic Co‑operation and Development [Internet]. [cited 2022 June 28]. Available from: http:// www.oecd.org/ health/ health‑systems/opioids.htm.
- Key Substance Use and Mental Health Indicators in the United States: Results from the 2016 National Survey on Drug Use and Health. Substance Abuse and Mental Health Services Administration [Internet]. [cited 2022 July 21]. Available from: https:// www.samhsa.gov/data/sites/default/files/NSDUH‑FFR1-2016/NSDUH‑FFR1-2016.htm#illicit8.
- Tisková zpráva agentury EU pro drogy v Lisabonu. Evropské monitorovací centrum pro drogy a drogovou závislost [Internet]. [cited 2021 March 21]. Available from: https://www.emcdda. europa.eu/ system/ files/attachments/13242/ HighlightsEDR 2020_ CS_Final_web . pdf.
- Národní konference Psychoaktivní léky 2020. Vláda ČR [Internet]. [cited 2021 February 28]. Available from: https://www.vlada.cz/cz/ ppov/protidrogova‑politika/koordinace/prezentace‑k-vystoupenim‑prednasejicich‑na‑on‑line‑konferenci‑psychoaktivni‑leky-2020-184398/.
- Celkové shrnutí vědeckého hodnocení perorálních opioidových přípravků s řízeným uvolňováním stupně III stupnice Světové zdravotnické organizace (WHO) pro léčbu bolesti (intenzivní přetrvávající bolest rezistentní k předchozím léčivým přípravkům). European Medicines Agency [Internet]. [cited 2022 March 21]. Available from: https://www.ema.europa.eu/en/documents/referral/modified‑release‑oral‑opioids‑article-31-referral‑annex‑ii_cs.pdf.
- Mastropietro DJ, Omidian H. Abuse‑deterrent formulations: part 1 - development of a formulation‑based classification system. Expert Opin. Drug Metab. Toxicol. [Internet]. 2014, 11(2), 193-204. [cited 2021 December 14]. Available from: doi:10.1517/17425255.2015.979786.
Go to original source... 
Go to PubMed... - Ahmad R, Omidian H. A cellulose‑based therapeutic polymer to deter intravenous drug abuse. Int. J. Pharm. [Internet]. 2020, 577 [cited 2021 December 12]. Available from: doi:10.1016/j.ijpharm.2020.119042. Go to original source... Go to PubMed...
- Maincent J, Zhang F. Recent advances in abuse‑deterrent technologies for the delivery of opioids. Int. J. Pharm. [Internet]. 2016, 510(1), 57-72 [cited 2022 October 30]. Available from: doi:10.1016/j.ijpharm.2016. 06. 012. Go to original source... Go to PubMed...
- Lu YX, Tang Y, Cui Y, et al. In vivo evaluation of risperidone‑SAIB in situ system as a sustained release delivery system in rats. Eur. J. Pharm. Biopharm. [Internet]. 2008, 68(2), 422-429 [cited 2021 November 11]. Available from: doi:10.1016/j.ejpb.2007. 05. 016. Go to original source... Go to PubMed...
- Romach MK, Schoedel KA, Sellers EM. Update on tamper‑resistant drug formulations. Drug Alcohol Depend. [Internet]. 2013, 130(1-3), 13-23 [cited 2021 March 11]. Available from: doi:10.1016/j.drugalcdep.2012. 12. 028. Go to original source...
- FDA podporuje vývoj inovativní léčvy závislosti na opiátech. [Internet] APATYKÁŘ. [cited 2020 December 13]. Available from: https:// lekarenstvi.apatykar.info/lekarenstvi‑ve‑svete/clanek-4443/.
- Abuse‑Deterrent Opioid Analgesics. U.S. Food and Drug Administration [Internet]. [cited 2020 October 12]. Available from: https://www.fda. gov/drugs/postmarket‑drug‑safety‑information‑patients‑and‑providers/abuse‑deterrent‑opioid‑analgesics.
- Principles for Evaluating the Abuse Deterrence of Generic Solid Oral Opioid Drug Products Guidance for Industry. U.S. Food and Drug Administration. [Internet]. [cited 2020 October 11]. Available from: https://www.fda.gov/regulatory‑information/search‑fda‑guidance‑documents/general‑principles‑evaluating‑abuse‑deterrence‑generic‑solid‑oral‑opioid‑drug‑products‑guidance.
- Čížek J. Léková závislost - stručný přehled a poznatky z praxe. Int. Med. Praxi [Internet]. [cited 2021 February 28]. Available from: https://www.internimedicina.cz/pdfs/int/2002/10/15.pdf.
- Kiššová L. Národní strategie protidrogové politiky: na období 2010-2018: [schválená usnesením vlády č. 340 ze dne 10. května 2010]. Praha: Úřad vlády České republiky, 2011.
- Rada vlády pro koordinaci protidrogové politiky. Vláda ČR [Internet]. [cited 2021 February 28]. Available from: https://www.vlada.cz/cz/ppov/protidrogova‑politika/ protidrogova‑politika-180471/.